1. Home
  2. LGCL vs ELTX Comparison

LGCL vs ELTX Comparison

Compare LGCL & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCL
  • ELTX
  • Stock Information
  • Founded
  • LGCL 2009
  • ELTX 2011
  • Country
  • LGCL China
  • ELTX United States
  • Employees
  • LGCL N/A
  • ELTX N/A
  • Industry
  • LGCL
  • ELTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LGCL
  • ELTX Health Care
  • Exchange
  • LGCL NYSE
  • ELTX Nasdaq
  • Market Cap
  • LGCL 119.4M
  • ELTX 121.7M
  • IPO Year
  • LGCL 2024
  • ELTX N/A
  • Fundamental
  • Price
  • LGCL $0.83
  • ELTX $9.89
  • Analyst Decision
  • LGCL
  • ELTX Strong Buy
  • Analyst Count
  • LGCL 0
  • ELTX 2
  • Target Price
  • LGCL N/A
  • ELTX $11.00
  • AVG Volume (30 Days)
  • LGCL 179.0K
  • ELTX 37.2K
  • Earning Date
  • LGCL 01-01-0001
  • ELTX 08-12-2025
  • Dividend Yield
  • LGCL N/A
  • ELTX N/A
  • EPS Growth
  • LGCL N/A
  • ELTX N/A
  • EPS
  • LGCL 0.07
  • ELTX N/A
  • Revenue
  • LGCL $145,690,427.00
  • ELTX N/A
  • Revenue This Year
  • LGCL N/A
  • ELTX N/A
  • Revenue Next Year
  • LGCL N/A
  • ELTX N/A
  • P/E Ratio
  • LGCL $12.12
  • ELTX N/A
  • Revenue Growth
  • LGCL N/A
  • ELTX N/A
  • 52 Week Low
  • LGCL $0.28
  • ELTX $3.70
  • 52 Week High
  • LGCL $3.31
  • ELTX $10.39
  • Technical
  • Relative Strength Index (RSI)
  • LGCL N/A
  • ELTX 75.55
  • Support Level
  • LGCL N/A
  • ELTX $9.14
  • Resistance Level
  • LGCL N/A
  • ELTX $10.39
  • Average True Range (ATR)
  • LGCL 0.00
  • ELTX 0.57
  • MACD
  • LGCL 0.00
  • ELTX 0.08
  • Stochastic Oscillator
  • LGCL 0.00
  • ELTX 79.34

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.

Share on Social Networks: